Zelira Therapeutics Limited (ZLDAF)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 0 | 1 | 2 | 0 | 0 | 0 | 0 | - |
| Operating profit | AUD m | -4 | -4 | ||||||
| Net profit | AUD m | -7 | -9 | -12 | -6 | -37 | -4 | -4 | - |
| EPS reported | AUD | -0.32 | -0.31 | ||||||
| Operating cashflow per share | AUD | -0.43 | -0.43 | ||||||
| Capex per share | AUD | 0.00 | 0.00 | ||||||
| FCF per share | AUD | -0.43 | -0.43 | ||||||
| Free cash flow | AUD m | -5 | -5 | ||||||
| Net debt | AUD m | 2 | 2 | ||||||
| Book value equity | AUD m | -4 | -4 | ||||||
| Book value per share | AUD | -0.39 | -0.38 | ||||||
| Number of shares | m | 11.48 | 11.62 | ||||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -1.09 | -1.09 | ||||||
| P/S LTM | x | 7,425.82 | 7,429.70 | ||||||
| P/FCF LTM | x | -0.99 | -0.99 | ||||||
| EV/EBITDA LTM | x | -1.73 | -1.73 | ||||||
| EV/Sales LTM | x | 10,681.58 | 13,276.45 | ||||||
| Earnings Yield LTM | % | -74.47% | -63.19% | ||||||
| FCF Yield | % | -100.73% | -100.73% | ||||||
| Quality | |||||||||
| ROE | % | +81.33% | +80.84% | ||||||
| ROIC | % | +1.84% | +1.29% | ||||||
| Operating margin | % | -6024.7% | -6024.7% | ||||||
| Gross margin | % | -1224.0% | -1224.0% | ||||||
| FCF/Sales | % | -747996.0% | -747996.0% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -99.31% | -99.31% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -2.29 | -2.29 | ||||||
| Net Debt/EBITDA | x | -0.53 | -0.51 | ||||||
| EBIT/Net interest | x | -9.71 | -9.71 | ||||||
| Net debt/market cap | % | +40.85% | +30.28% | ||||||
| Net debt/Equity | x | -0.44 | -0.44 | ||||||
| Gross debt/equity | x | -0.48 | -0.48 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Zelira Therapeutics Limited is an Australian biopharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-derived therapeutic agents, aimed at treating a variety of medical conditions. The firm offers its HOPE brand formulations in Pennsylvania and Louisiana, and is actively developing Zenivol, a cannabinoid-based medicine specifically designed for chronic insomnia. Beyond its prescription products, Zelira also markets several over-the-counter (OTC) items, including SprinJene for oral care and RAF FIVE for dermatological applications. A notable OTC offering is ITURA, an advanced topical cream formulated to alleviate multiple symptoms such as numbness, tingling sensations, muscle cramps, reduced sensitivity, and pain frequently associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has cultivated strategic partnerships with prominent institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Incorporated in 2003, the company, which officially changed its name from Zelda Therapeutics Limited in December 2019, maintains its corporate headquarters in Perth, Australia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Zelira Therapeutics Limited is an Australian biopharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-derived therapeutic agents, aimed at treating a variety of medical conditions. The firm offers its HOPE brand formulations in Pennsylvania and Louisiana, and is actively developing Zenivol, a cannabinoid-based medicine specifically designed for chronic insomnia. Beyond its prescription products, Zelira also markets several over-the-counter (OTC) items, including SprinJene for oral care and RAF FIVE for dermatological applications. A notable OTC offering is ITURA, an advanced topical cream formulated to alleviate multiple symptoms such as numbness, tingling sensations, muscle cramps, reduced sensitivity, and pain frequently associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has cultivated strategic partnerships with prominent institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Incorporated in 2003, the company, which officially changed its name from Zelda Therapeutics Limited in December 2019, maintains its corporate headquarters in Perth, Australia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free